Morning Snapshot
Market Pulse: Midweek trading kicks off with a tech and biotech rally alongside a crypto surge, snapping yesterday’s flat mojo as digital assets and drugmakers seize the spotlight.
Key Movers: eToro’s Q4 crypto-fueled earnings beat sent its shares skyrocketing, while Novartis’ Phase III win in chronic inducible urticaria and fresh merger chatter around Netflix, WBD, and Paramount grabbed headlines.
Macro & Politics: A Bank of America survey flags record bearish dollar bets, underscoring growing institutional doubt about the greenback’s dominance just as Fed minutes loom.
What’s Next: Eyes turn to Fed minutes for any hint of rate pivots, biotech conferences for RemIND updates, and media stocks for fresh merger moves.
Unfiltered Market Commentary
Everyone’s overlooking how the eToro earnings rebound isn’t just about crypto volumes—it’s a signal of retail traders flexing muscles that institutional desks can't ignore (see “eToro shares pop 20% as crypto revenues bolster Q4 earnings,” Cointelegraph). Too many folks are stuck on Bitcoin’s price swings and missing that retail’s mania could f**king drive broader broker strategies this year.
There’s a hidden parallel between Novartis clearing its Phase III hurdle (“Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU),” GlobeNewswire) and Netflix granting WBD a waiver to reopen talks with Paramount (“Netflix Allows Warner Bros. Discovery to Restart Takeover Deal Talks With Paramount Skydance,” Breitbart News). Both stories hinge on regulatory green lights deciding if a blockbuster drug or a mega-merger truly launches—regulators hold the keys to breakthroughs in labs and boardrooms alike.
If you’re still dithering, it’s time to pick a side—load up on speculative biotech plays ahead of FDA filings or brace for volatility in media names as merger negotiations heat up. Don’t just watch the next data drop; stake your claim around catalysts that actually move markets.
📈 Breaking Financial News
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU). The primary endpoint was met for the three most prevalent types of CIndU: sympto…
4 data points suggest XRP price bottomed at $1.12: Are bulls ready to take over?
Multiple onchain and derivatives metrics show short-selling pressure failing to push XRP prices lower. Will the balance tip back toward the bulls any time soon?
eToro shares pop 20% as crypto revenues bolster Q4 earnings
eToro CEO Yoni Assia says he is positioning the trading platform “for a financial system that is increasingly moving on-chain,” after its crypto revenues boosted earnings in Q4.
Is Nail Refresh Foot Fungus Oil Legit? What Consumers Should Know About This Botanical Toenail Care Formula
Nail Refresh introduces a botanical essential oil blend for topical toenail care featuring Tea Tree, Oregano, and Clove Bud Oil ingredients….
The Comeback of the Century: Wall Street Wrote Him Off…
But Elon's $3 Trillion Comeback Could Begin Soon Elon Musk was declared washed up and finished. But any day now, he could unveil a new technology that outshines Tesla, SpaceX, even PayPal… a breakthrough big enough to solve America's toughest problem, make President Trump a hero to the Western World… and spark a $3 trillion boom. Early investors could see massive gains. Details here.
🔍 Market Analysis & Insights
Genmab Publishes 2025 Annual Report
Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025….
Machi Big Brother vs. the market: Why is he still betting big on Bitcoin and Ethereum?
Bitcoin continued to spread weakness across cryptocurrencies on 17th of February 2026. Risk appetite fractured […]
Here’s Why Establishment Labs Holdings (ESTA) Soared in Q4
Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Small Cap Growth Fund…
Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics
Key applications of facial injectables include wrinkle reduction, facial line correction, and enhancement of facial features. The market is segmented by type (Derma Fillers and Neuromodulator Aesthetics), application (Facial Line Correction, Face Lift), and e…
Netflix Allows Warner Bros. Discovery to Restart Takeover Deal Talks With Paramount Skydance
Warner Brothers Discovery is reconsidering the latest purchase bid by Paramount Skydance after taking more time to look over the company's amended purchase offers. Netflix has granted Warner Bros. Discovery a waiver on Tuesday to reopen deal talks.…
“This man is my kind of contrarian” Renowned Futurist, Eric Fry, has been seen o
“Nvidia, Amazon and Tesla are ticking time bombs in investors' portfolios,” he says. Instead, he's sharing three NEW stocks positioned to take over as the tech kingpins of tomorrow. Get Eric's full “Sell This, Buy That” list right here.
💰 Investment Opportunities
Broker’s Call: GMR Airports (Buy)
Elara Securities recommends a Buy for GMR Airports, raising the target price to ₹140 after strong Q3FY26 earnings.
Hemostasis Products Market Size to Reach USD 3.28 Billion by 2035 with 5.41% CAGR – SNS Insider
According to SNS Insider Research, Hemostasis Products Market Growth is Driven by Rising Surgical Volumes, Trauma Incidence, and Accelerating Demand for Advanced Bleeding Control Technologies.…
Warner Bros. Discovery Sets Netflix Deal Vote, Will Talk to Paramount
WBD says that Netflix is giving it seven days to talk to the David Ellison-led company to try and resolve outstanding concerns and secure a “best and final” bid, but that it still recommends the Netflix deal.
The Cross-Chain Giant Set for 1,000%+ Gains As crypto markets surge post-tariffs
Its transaction volume is skyrocketing across all major blockchains while its price remains suppressed as retail has yet to discover it – creating a coiled spring ready to release. Breaking: Access our urgent research on this cross-chain opportunity for just $3!